AbL Diagnostics Aktie

ABL Diagnostics has been awarded by the Commercial Court of Évry the takeover of the assets and business operations of TEXCELL. The transaction includes strategic intangible and tangible assets (€225,000), inventories, leasing obligations and an economic project volume of about €2.9 million, financed from the group's available funds. ABL takes on 29 employees, will continue operations at the Genopole site in Évry-Courcouronnes and plans investments of roughly €930,000 as well as an increase in working capital of around €1 million. TEXCELL generated about €5.4 million in revenue in 2024; ABL views the acquisition as a complement to its molecular diagnostics and bioanalysis activities. » Więcej na de.investing.com

ABL Bio agreed a licensing and joint research deal with Eli Lilly for its Grabody-B blood-brain-barrier-penetrating bispecific antibody platform, bringing $40 million upfront and up to $2.56 billion in milestones. The pact, together with prior large deals with GSK and Sanofi, drove an about 80% share surge and made founder and CEO Lee Sang-hoon, who holds a 23% stake, a billionaire. ABL Bio reported first-half revenue of 77.9 billion won and a profit of 11.7 billion won, with all revenue from technology transfer deals, and recently led a $75 million investment in NEOK Bio. » Więcej na forbes.com